Dr. Kevin Hay is a Clinician Scientist at the Terry Fox Laboratory and Leukemia/Bone Marrow Transplant Program of BC in Vancouver. Dr. Hay received a Master of Science in Immunology at the University of Manitoba (2008), followed by an MD (2011). After completing residency in Internal Medicine (2014) and a clinical fellowship in Haematology (2016) at the University of British Columbia, he was awarded a scholarship through the Clinician Investigator Program of UBC to pursue a postdoctoral fellowship in cellular immunotherapy which he completed at the Fred Hutchinson Cancer Research Center in Seattle Washington under the mentorship of Dr. Cameron Turtle. Dr. Hay’s research focuses on understanding the unique toxicities associated with chimeric antigen receptor T (CAR-T) cells, as well as the development of novel CAR-T cell therapies.

Affiliations

Clinical Scientist and Hematologist, The Leukemia/Bone Marrow Transplant Program of BC, BC Cancer

Credentials

Professional Experience

Scientist, Terry Fox Laboratory

Assistant Professor, Medicine, University of British Columbia (UBC)

Clinician Scientist, and Hematologist,
The Leukemia/Bone Marrow Transplant Program of BC, BC Cancer

Medical Director, Clinical Cell Therapy, BC Cancer

Post-Graduate Training

Postdoctoral Research Fellow, Cellular Immunotherapy (Supervisor: Dr. Cameron Turtle),
Fred Hutchinson Cancer Research Center, 2016 – 2018

Clinical Investigator Program Fellow in Cellular Immunotherapy,
University of British Columbia, 2016 – 2018

Hematology Fellow, University of British Columbia, 2014 – 2014

Internal Medicine Resident, University of British Columbia, 2011 – 2014

Education

MD (Medicine), University of Manitoba, 2007 – 2011

MSc (Immunology), University of Manitoba, 2005 – 2018

BSc (Biology (Honors) and Chemistry),  Trinity Western University, 1999 – 2005

Selected Publications

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Blood, 2019
Hay, Kevin A, Gauthier, Jordan, Hirayama, Alexandre V, Voutsinas, Jenna M, Wu, Qian, Li, Daniel, Gooley, Ted A, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S, Hawkins, Reed M, Vakil, Aesha, Steinmetz, Rachel N, Schoch, Gary, Chapuis, Aude G, Till, Brian G, Kiem, Hans-Peter, Ramos, Jorge D, Shadman, Mazyar, Cassaday, Ryan D, Acharya, Utkarsh H, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Blood, 2019
Hirayama, Alexandre V, Gauthier, Jordan, Hay, Kevin A, Voutsinas, Jenna M, Wu, Qian, Gooley, Ted, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S, Hawkins, Reed M, Vakil, Aesha, Steinmetz, Rachel N, Acharya, Utkarsh H, Cassaday, Ryan D, Chapuis, Aude G, Dhawale, Tejaswini M, Hendrie, Paul C, Kiem, Hans-Peter, Lynch, Ryan C, Ramos, Jorge, Shadman, Mazyar, Till, Brian G, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J
Back to top